NVONovo Nordisk A/S
Is it safe?
Mostly sound, with a caveat: comfortable debt (AA), but big price swings.
Rock-solid balance sheet, low leverage. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -75% · now 37% below its 52-week high.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can NVO take a bad year?
Novo Nordisk A/S carries $116.0B of net debt at 0.78× EBITDA: a load its earnings can carry.
Net debt · as at FY2025 · under two and a half years of EBITDA, comfortable
- Net debt / EBITDA
- 0.78×
Net debt / EBITDA · 0.61× a year ago · the load is going up
- Interest cover
- 30.3×
Interest cover · operating profit covers the interest bill several times over
- Annualised volatility
- 48%
Annualised volatility · roughly twice as jumpy as the market
Details›
- Total debtFY2025
- $143.0B
- Cash and short-term investments
- $27.0B
- Net debt
- $116.0B
- EBITDA, trailing twelve months
- $149.6B
- Operating profit, trailing twelve months
- $127.7B
- Debt / equity
- 0.74×
- Total debt / EBITDA
- 0.95×
- Annualised volatilitytwo years of daily moves
- 48%
- Worst drawdown on file
- −75%
- Below its 52-week high
- 37%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Drug Manufacturers, General
Ranks #1 of 7 by RyuScore